Here are the latest stories being discussed in biopharma today:

Headline: AstraZeneca Reports Promising Advanced Breast Cancer Trial Results

AstraZeneca’s experimental PARP1 inhibitor, saruparib, has demonstrated efficacy in advanced breast cancer patients, shrinking tumors in nearly 50% of cancer sufferers with certain DNA repair defects. Despite alternative PARP inhibitors on the market causing significant side effects, research suggests PARP1 is key to the inhibitors’ efficacy, fuelling hopes that the targeted saruparib will have an improved safety profile and prolonged patient tolerance.

Headline: Merck Acquires Abceutics to Improve ADC Safety

Merck has acquired Abceutics